LIMINATUS PHARMA, INC. Operating Income
LIMINATUS PHARMA, INC. (LIMN) reported Operating Income of -$1.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-14
- LIMINATUS PHARMA, INC. operating income (loss) for the quarter ending 2026-06-30 was -$1.38M.
- LIMINATUS PHARMA, INC. operating income (loss) for the quarter ending 2026-03-31 was -$1.10M.
- LIMINATUS PHARMA, INC. operating income (loss) for the quarter ending 2025-12-31 was -$884.21K.
- LIMINATUS PHARMA, INC. operating income (loss) for the quarter ending 2025-09-30 was -$701.17K.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.38M 10-Q · filed 2026-08-14 | -$2.48M 10-Q · filed 2026-08-14 | -$3.36M derived: sum of 3 quarters · filed 2026-08-14 | -$4.07M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$1.10M S-1 · filed 2026-06-24 | -$1.99M derived: sum of 2 quarters · filed 2026-06-24 | -$2.69M derived: sum of 3 quarters · filed 2026-06-24 | -$3.80M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$884.21K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | -$1.59M derived: sum of 2 quarters · filed 2026-06-24 | -$2.70M derived: sum of 3 quarters · filed 2026-08-14 | -$2.97M S-1 · filed 2026-06-24 | |
| 2025-09-30 | -$701.17K 10-Q · filed 2025-11-14 | -$1.82M derived: sum of 2 quarters · filed 2026-08-14 | -$2.08M 10-Q · filed 2025-11-14 | -$2.25M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$1.12M 10-Q · filed 2026-08-14 | -$1.38M 10-Q · filed 2026-08-14 | -$1.55M derived: sum of 3 quarters · filed 2026-08-14 | -$2.09M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$264.22K S-1 · filed 2026-06-24 | -$255.00 10-Q · filed 2025-06-02 | -$431.30K derived: sum of 2 quarters · filed 2026-06-24 | -$974.44K derived: sum of 3 quarters · filed 2026-06-24 | -$1.88M derived: sum of 4 quarters · filed 2026-06-24 |
| 2024-12-31 | -$167.08K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | -$710.22K derived: sum of 2 quarters · filed 2026-06-24 | -$1.62M derived: sum of 3 quarters · filed 2026-06-24 | -$3.33M S-1 · filed 2026-06-24 | |
| 2024-09-30 | -$543.15K 10-Q · filed 2025-11-14 | -$1.45M derived: sum of 2 quarters · filed 2025-11-14 | -$3.16M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$909.22K 10-Q · filed 2025-10-06 | -$2.62M 10-Q · filed 2025-10-06 | |||
| 2024-03-31 | -$247.00 10-Q · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |